
World's first silicon-based quantum computer is small enough to plug into a regular power socket
Equal1 representatives unveiled Bell-1 on March 16 — a new six- qubit machine that can fit seamlessly into existing HPC environments like data centers, company representatives said in a statement .
The machine tips the scale at slightly more than 440 pounds (200 kilograms) but it's rack-mountable — meaning it can be mounted onto a physical rack in a data center — and it's roughly the same size as existing graphics processing unit (GPU) servers.
Unlike other quantum computers, the Bell-1 doesn't require specialized infrastructure to deploy, and it doesn't need additional equipment to be cooled to near-absolute zero.
Related: China achieves quantum supremacy claim with new chip 1 quadrillion times faster than the most powerful supercomputers
That's because it boasts its own self-contained, closed-cycle cryo cooling unit, which enables the system to operate at a remarkable 0.3 kelvin, or minus 459.13 degrees Fahrenheit (minus 272.85 degrees Celsius).
The machine makes use of the latest semiconductor fabrication techniques as well as purified silicon , which allows for a high level of control and long coherence times (a qubit's ability to exist in multiple states simultaneously, which is crucial for quantum algorithms and computations).
Get the world's most fascinating discoveries delivered straight to your inbox.
Rack-mountable quantum computing
The Bell-1's qubits are silicon-based, meaning they're smaller than conventional qubits, and the chip at the heart of the machine incorporates quantum processor units (QPUs) with Arm CPUs — traditional processors known for their small size and efficiency — and neural processing units (NPUs) — specialized processors for accelerating machine learning and artificial intelligence (AI).
Incorporating all these elements onto a single chip eliminates the complex orchestration that would otherwise be necessary between classical and quantum computing elements. As long as you've got the space in a rack, all it requires is a standard electrical outlet: plug it in and it's ready to work, Equal1 representatives said.
(Image credit: Fergal Phillips)
The company's chip, called the UnityQ 6-Qubit Quantum Processing System, utilizes spin qubits, in contrast to many quantum computing platforms that rely on either trapped-ion or superconducting qubits. Silicon-based spin qubits are compact, leading to potentially higher qubit density, and could leverage existing semiconductor fabrication techniques, meaning more scalability.
The chip fitted into the Bell-1 also incorporates error correction, control and readout, while taking advantage of existing semiconductor infrastructure for reliability and scalability.
Although this first generation of the chip includes six qubits, the company wants to make more powerful versions with a higher qubit count. The Bell-1 is also future-proof in that early adopters can upgrade existing systems as new models are rolled out, rather than replacing them with new machines, company representatives added.
The Bell-1 builds on advances first published by the company in December 2024, which established new peak performance marks for silicon qubit arrays as well as quantum controller chips.
These included the world's highest recorded single-qubit and two-qubit gate fidelity (meaning fewer errors) and gate speed (meaning faster operations). The platform also utilizes a specialized, AI-powered error correction system developed in partnership with Arm.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Axios
24 minutes ago
- Axios
Colorado lawmakers tap reserve, end tax breaks to fill budget gap
Democratic leaders at the state Capitol outlined plans Tuesday to increase taxes, cut services and tap reserve funds to close a $1 billion budget hole spurred by President Trump's "big, beautiful bill." State of play: The legislation will generate fierce debate about how the state should manage its money when lawmakers return Thursday for a special legislative session. The core of the Democratic plan eliminates a handful of corporate tax breaks worth a combined $300 million to $400 million. The five-bill package will limit the business tax deduction, remove corporate tax breaks on foreign-sold goods and crack down on corporate profit shifting to tax haven countries. The intrigue: The most controversial proposal is lowering the state's 15% financial reserve by $200 million to $300 million, dropping it to 13% at a time when fiscal analysts are warning about a potential recession. Yes, but: Those moves are not enough to close a roughly $750 million gap. Instead, lawmakers will punt $300 million in spending cuts to balance the $44 billion state budget to the governor in consultation with the legislative Joint Budget Committee in the coming weeks. The governor is expected to move quickly to implement cuts by Sept. 1. What they're saying: "We're looking forward to rolling up our sleeves and making sure we can maintain strong fiscal stewardship here in Colorado," Gov. Jared Polis told Axios Denver in a recent interview. Between the lines: More than most states, Colorado is susceptible to changes in federal taxes because they affect state income taxes. The federal tax bill, known as H.R. 1, reduced the state's individual and corporate income taxes by an estimated $1.2 billion, according to the governor's office. The other side: Republican state lawmakers are touting the cuts from Trump's tax bill and pushing back against Democratic efforts to generate new tax revenue, suggesting spending cuts are what is most needed. Sen. Byron Pelton (R-Sterling) plans to introduce legislation requiring voter approval for any bill that changes state tax liability caused by federal tax law. What's next: Beyond the budget, Democratic lawmakers also plan to introduce legislation to stabilize the state's health care marketplaces amid projections that thousands of residents could lose their insurance and enable Planned Parenthood to accept Medicaid payments.
Yahoo
an hour ago
- Yahoo
Hims & Hers Fuels Growth via Market Expansion and New Care Verticals
The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, is building its market opportunity around democratizing access to personalized healthcare, particularly in areas that have historically been underserved. By the second quarter of 2025, the platform had grown to 2.4 million subscribers supported by nearly 1,500 licensed providers. Its weight loss specialty, anchored in GLP-1 treatments, highlights the strength of its model, delivering retention rates above industry averages thanks to continuous provider engagement and integrated digital support. Hims & Hers is preparing to expand further into hormonal health with offerings that target menopause and low testosterone, conditions representing a large U.S. market opportunity. Integrated lab testing and a broader shift toward longevity and preventive care are expected to increase patient lifetime value while positioning it as more than just a treatment provider. Instead, HIMS aims to play a role in long-term health optimization and proactive care. International expansion is another powerful growth driver. The acquisition of ZAVA extends Hims & Hers' footprint across the U.K., Germany, France and Ireland, granting immediate access to more than 1.3 million existing patients and strengthening its position as a global digital health leader. Planned entry into Canada in 2026, aligned with the introduction of generic semaglutide, will likely make weight loss treatments significantly more affordable and accessible for a population where obesity rates remain high. Together, vertical integration, entry into new therapeutic categories and global expansion underscore Hims & Hers' capacity to sustain momentum and capture long-term market share. LFMD & AMWL's Market Opportunities and Growth Drivers LifeMD, Inc.'s LFMD market opportunity centers on scaling a vertically integrated, subscription telehealth platform across primary care and lifestyle conditions. LFMD is adding commercial insurance and Medicare coverage pathways, expanding reach and conversion. Growth drivers include LifeMD's owned pharmacy with planned non-sterile compounding, enabling cost and fulfillment control, a GLP-1 weight-management program with tens of thousands of subscribers and B2B partnerships for at-home labs and remote monitoring (Ash Wellness, Withings) that deepen personalization and retention. LifeMD's telehealth revenues grew 29.7% year over year in second-quarter 2025, underscoring sustained demand. American Well Corporation's AMWL, popularly known as Amwell, market opportunity is tied to enterprise, payer and government modernization of care. Amwell's platform powers the Military Health System's virtual visits worldwide, replacing MHS Video Connect. This change has nearly tripled virtual visit volumes. A one-year extension sustains this presence across about 9.6 million beneficiaries. Amwell's growth drivers include increasing subscription software mix, new wins like Florida Blue and AI-enabled efficiency as it targets positive operating cash flow in 2026. Amwell continues positioning as a unified, tech-enabled care platform for large systems. HIMS' Price Performance, Valuation and Estimates Shares of Hims & Hers have gained 86.5% year to date, outperforming the industry's growth of 23.5%. Image Source: Zacks Investment Research HIMS' forward 12-month P/S of 3.8X is lower than the industry's average of 5.8X, but is higher than its three-year median of 2.4X. It carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for HIMS' 2025 earnings per share suggests a 137% improvement from 2024. Image Source: Zacks Investment Research Hims & Hers stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report American Well Corporation (AMWL) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report LifeMD, Inc. (LFMD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research

Yahoo
3 hours ago
- Yahoo
Viking Therapeutics stock falls 37% on high dropout rate in obesity trial
-- Viking Therapeutics (NASDAQ:VKTX) stock plunged as much as 37% Tuesday after revealing results from its Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment, while Eli Lilly (NYSE:LLY) shares gained 1.5% as analysts pointed to competitive advantages. The trial demonstrated that Viking's oral tablet formulation of VK2735, a dual GLP-1 and GIP receptor agonist, met its primary endpoint with patients losing up to 12.2% of body weight after 13 weeks compared to 1.3% for placebo. Despite the weight loss efficacy, the 28% treatment discontinuation rate among patients receiving VK2735 versus 18% for placebo raised significant concerns among investors and analysts. Mizuho analyst Jared Holz highlighted competitive disadvantages compared to Eli Lilly's offerings: "Data look inferior to LLY on almost all metrics and the thing to consider here is that patients discontinued at such a high rate over 13-weeks vs. LLY in the mid 20% range --- but over 72-weeks; A much longer trial, and therefor LLY looks far better head-to-head. This probably shutters hope for VKTX a bigtime player in the oral obesity market over the near to medium term." JPMorgan (NYSE:JPM) analyst Hardik Parikh offered a more balanced view, noting, "In 13 weeks, the three highest-dosing arms of 60/90/120mg showed avg pbo-adj weight loss of ~7.5%, 10%, 11%, which we think is very strong compared with other orals in development. Tolerability overall was manageable, but it was worse than we expected based on the ph1 performance." Parikh added that while the adverse event profile wasn't as clean as in Phase 1 trials, "we still think oral vk-2735 offers strong efficacy with a manageable tolerability profile." Viking reported that 99% of gastrointestinal-related adverse events were mild or moderate. The company also highlighted an exploratory maintenance dosing arm showing weight loss could be maintained at lower doses. The major adverse events included vomiting rates of 20-35% in the three highest dose arms compared to about 10% for placebo, and nausea rates of approximately 58% for patients on treatment versus 48% for placebo. Related articles Viking Therapeutics stock falls 37% on high dropout rate in obesity trial Tesla robotaxi trial impresses, pricing power clear: William Blair Palo Alto Networks gains after strong earnings and Bank of America upgrade